 Subjects will participate in this study for approximately 8 months, during which 5 visits will be scheduled, and phone contact will be made on Day 1, Day 8, and every 2 months thereafter for up to 6 months post-Day 21 visit Day 201. Blood samples will be collected for immunogenicity analyses at Days 0 and 21 for all subjects. Safety laboratory assessments will be performed at Screening, on Day 3 and within 48 hours of Day 3 results availability, for grade 3 or grade 4 abnormalities or if deemed necessary by the investigator or early termination. Subsequent follow-up of clinically significant laboratory abnormalities will be done according to the investigators discretion.. Subjects will be monitored throughout the study for safety, including the reporting of solicited local and systemic reactions. 